GPLD1 antibody (AbBy Fluor® 594)

Catalog No. ABIN2813949

Product Details anti-GPLD1 Antibody (AbBy Fluor® 594)

Target: GPLD1 (Glycosylphosphatidylinositol Specific phospholipase D1 (GPLD1))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This GPLD1 antibody is conjugated to AbBy Fluor® 594

Application: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Cross-Reactivity: Human, Mouse, Rat

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human GPLD1/GPI-PLD

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for GPLD1

Target: GPLD1 (Glycosylphosphatidylinositol Specific phospholipase D1 (GPLD1))

Alternative Name: GPLD1 (GPLD1 Products)

Background:

Synonyms: Glycoprotein phospholipase D, Glycosyl-phosphatidylinositol-specic phospholipase D, GPI-PLD, GPI-specic phospholipase D, GPIPLD, GPIPLDM, GPLD1, PHLD_HUMAN, Phosphatidylinositol glycan specic phospholipase D, Phosphatidylinositol-glycan-specic phospholipase D, PI-G PLD, PIGPLD, PIGPLD1.

Background: Phosphatidylinositol-glycan-specific phospholipase D (GPI-PLD) is a high-density lipoprotein-associated protein found on chromosome 6p22 that specifically hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol-glycans (PI-Gs). GPI-PLD is found in serum, liver, cerebrospinal fluid and in milk. The majority of plasma GPI-PLD appears to be specifically associated with a small, discrete and minor fraction of lipoproteins containing apoA-I and apoA-IV. Serum GPI-PLD activity is reduced over 75 % in systemic inflammatory response syndrome and the downregulation of GPI-PLD could play an important role in the control of proinflammatory responses.

Gene ID: 2822

Pathways: Inositol Metabolic Process, Regulation of Carbohydrate Metabolic Process